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INTRODUCTION
The retinal pigment epithelium (RPE) is a polarized monolayer of 
epithelial cells that rests on Bruch’s membrane, between the chorio-
capillaries and the neural retina. RPE cells create the external blood–
retina barrier and have multiple roles in maintaining photoreceptor 
health and visual function: they are involved in retinol recycling, 
absorption of stray light, nutrient transport, phagocytosis of pho-
toreceptor outer segments (OS), and trophic factor secretion.1,2 
RPE dysfunction, which usually leads to the damage and death of 
photoreceptor cells, occurs in several retinal dystrophies (RD), such 
as retinitis pigmentosa (RP), which is the most frequent inherited 
RD with a prevalence of 1:4,000 and more than 1 million people 
affected worldwide.3,4 To date, more than 60 different genes and 
over 3,000 different disease alleles have been associated with classi-
cal forms of RP. Whether this great genetic heterogeneity ultimately 
converges on one or several retinal cell death pathways is poorly 
understood, and this lack of knowledge has hindered the efforts to 
elucidate efficient therapeutic strategies.5
Some of the current therapeutic approaches for RD use gene 
delivery systems, treatment with neurotrophic growth factors, 
antiapoptotic agents, ribozyme therapy, RNA interference, dietary 
supplementation, or cell replacement.6 However, most of these 
treatments are only effective in preventing or slowing down the 
progression of the dystrophy, and are less efficient when used 
to treat advanced stages of the disease.7 Within this context, cell 
therapies are able to reverse degeneration and vision loss to a 
greater extent than any other treatment available.5 In fact, over 
the past decade, studies with pluripotent stem cells (PSCs) for dis-
ease modelling and treatment of incurable diseases have gained 
momentum in the field of regenerative medicine.8 The ability of 
PSCs to provide an unlimited supply of viable and specialized cell 
types, together with the advantages of the retina for this kind of 
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Retinal dystrophies (RD) are major causes of familial blindness and are characterized by progressive dysfunction of 
 photoreceptor and/or retinal pigment epithelium (RPE) cells. In this study, we aimed to evaluate and compare the therapeutic 
effects of two pluripotent stem cell (PSC)-based therapies. We differentiated RPE from human embryonic stem cells (hESCs) 
or human-induced pluripotent stem cells (hiPSCs) and transplanted them into the subretinal space of the Royal College of 
Surgeons (RCS) rat. Once differentiated, cells from either source of PSC resembled mature RPE in their morphology and gene 
expression profile. Following transplantation, both hESC- and hiPSC-derived cells maintained the expression of specific RPE 
markers, lost their proliferative capacity, established tight junctions, and were able to perform phagocytosis of photorecep-
tor outer segments. Remarkably, grafted areas showed increased numbers of photoreceptor nuclei and outer segment disk 
membranes. Regardless of the cell source, human transplants protected retina from cell apoptosis, glial stress and accumula-
tion of autofluorescence, and responded better to light stimuli. Altogether, our results show that hESC- and hiPSC-derived 
cells survived, migrated, integrated, and functioned as RPE in the RCS rat retina, providing preclinical evidence that either 
PSC source could be of potential benefit for treating RD.
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therapy (i.e., the eye is easily accessible, the clear media permits 
direct visualization following intervention, and the immune privi-
lege conferred by blood-retina barrier), make of cell therapy one 
of the most promising treatments for RD.9 At present, all major ret-
inal cell types, RPE cells among them, can be differentiated from 
both human embryonic stem cells (hESCs) and human-induced 
pluripotent stem cells (hiPSCs).10–14 The success in the use of such 
cells as biological therapy will depend on the ability of grafted 
cells to survive after transplantation, migrate toward the desired 
location and differentiate into functional target cells.15
The Royal College of Surgeons (RCS) rat is a good model for explor-
ing potential treatment approaches for RD.16,17 These animals harbor 
a mutation in the gene that encodes MERTK, a transmembrane tyro-
sine kinase expressed in RPE cells that plays a crucial role in the signal 
transduction pathway involved in the phagocytosis of photorecep-
tor OS.18 In this animal model, apoptosis of photoreceptors arises 
from the third week of age and progressively affects the majority of 
cells, producing a severely impaired retinal function at 2–3 months.19 
Several cell types have been tested for RPE cell replacement in this 
model, including RPE and non-RPE immortalized cell lines,16,20–27 RPE 
derived from hESCs,12,28 and RPE derived from hiPSCs.29,30 When the 
intervention was performed at early stages of the disease, these 
studies achieved successful morphological and functional rescue. 
However, further studies are needed to elucidate whether cell ther-
apy may be effective if introduced at later stages of degeneration. 
This is clinically important, as cell-based therapies are more likely to 
be applied at a time when the vision in most patients is already com-
promised. Moreover, a comprehensive study comparing the use of 
the two types of PSCs is still lacking. Within this context, we aimed at: 
(i) developing a well-defined culture protocol to direct the differentia-
tion of hESC and hiPSC lines into RPE cells, (ii) transplanting them into 
the subretinal space of RCS rats at postnatal day 21 or 42 (P21 or P42), 
(iii) assessing their migration, integration, survival and functionality, 
and (iv) determining any differences between the two PSC types.
ReSUlTS
Differentiation and expansion of human ES and iPS cell lines into 
mature RPE
Both hESC and hiPSC lines were successfully differentiated into 
RPE-like cells using a 12-week protocol in which PSCs, cultured 
on Matrigel-coated dishes, were kept in RPE-specific medium 
until the end of the experiment (see Supplementary Materials 
and Methods and Supplementary Figure S1a). Pigmented cells 
that appeared in the culture after 5 weeks were purified by 
hand picking at week 6, and homogeneous cultures consisting 
on pigmented epithelial monolayer cobblestone-shaped cells 
could be obtained and expanded from either PSC source (see 
Supplementary Figure S1b).
Transmission electron microscopy revealed the typical morphol-
ogy and structural characteristics of RPE, including the presence 
of melanosome granules, polarized monolayer cell distribution 
with apical microvilli and tight junctions between cells (Figure 1a). 
Comparable results were obtained with both cell lines and were 
reproducible in different experiments (data not shown).
Expression profile of differentiated cells
Homogeneous RPE cell cultures were positive for the expression of 
several neural retina markers such as PAX6, OTX2, and CHX10; and 
for the RPE-specific markers BEST1, MITF, RPE65, and the tight junc-
tion marker ZO-1 (Figure 1b).
Quantitative real-time PCR analyses of RPE differentiated from 
hESCs and hiPSCs showed a progressive decrease in the expres-
sion of the pluripotency marker OCT3/4, and increased expres-
sion of genes essential for eye development, such as the neural 
markers PAX6 and RX, the visual cycle gene CRALBP, the genes 
encoding the transcription factors MITF and OTX2, the pig-
ment synthesis-related gene SILVER (SIL), the phagocytic marker 
MERTK, and the gene encoding the pigment  epithelium-derived 
factor and neurotrophic factor (PEDF) (Figure  1c). Except for 
OTX2, the expression of which was approximately threefold 
higher in hiPSC-derived RPE cells compared with those differ-
entiated from hESC, the expression level of genes related with 
retina/RPE development was similar in RPE cells derived from 
either PSC source.
Human PSC-derived RPE cells survive in the rat subretinal space 
and integrate within the host RPE
RCS rats were injected subretinally with RPE cells differentiated 
from hESC or hiPSC (RPE-injected eyes), or with differentiation 
medium alone (sham-injected eyes) (see Supplementary Video S1 
and Table 1). To avoid the introduction of transgenic markers such 
as GFP, which could increase the risk of altering gene expression or 
cellular functions, human cells were transiently stained with a green 
fluorescent dye (CellTracker), which allowed tracking the cell grafts 
in vivo for the first 5–6 days after transplantation (Figure 2a).
At 5 weeks postinjection (PI), human cells were found integrated 
into the rat retina as scattered single-cell units, occupying the sub-
retinal space as extensive laminar sheets, or in discrete rosette-like 
formations (Figure 2b). Grafted cells were never observed within the 
cellular layers of the neurosensory retina.
To study the distribution and integration of human transplants 
further, we isolated the posterior pole of transplanted eyes and 
removed the retina to expose whole RPE monolayers. In all RPE-
injected eyes (5 weeks PI, n  =  4; 8 weeks PI, n  =  6 and 12 weeks 
PI, n = 8), human RPE grafts covered an area comparable with the 
original bleb observed by color fundus imaging on the day of injec-
tion (see Supplementary Figure S2). We also found that human cells 
formed tight junctions between each other and established asso-
ciations with the host tissue in all cases examined up to 12 weeks PI 
(Figure 2c). Comparable distribution and integration patterns were 
observed in transplants of RPE cells differentiated either from hESCs 
or hiPSCs.
Expression of RPE-specific markers and phagocytosis of host OS by 
transplanted cells
After observing that grafts derived from both hESCs and hiPSCs 
properly integrated into rat retinas, we determined if such RPE trans-
plants continued to express RPE markers such as CRALBP, which was 
expressed by the same cells before transplantation at the end of the 
in vitro differentiation process (Figure 1c). We found that hESC- and 
hiPSC-derived RPE cells were able to maintain CRALBP expression 
for at least 5 weeks PI. Moreover, most RPE cells were nonprolifera-
tive as shown by immunostaining of Ki67 (Figure 3a).
To determine the phagocytic ability of the transplanted cells in 
vivo, a human-specific marker antibody cocktail (HSM) was used 
together with an antirhodopsin antibody. We were able to dem-
onstrate endocytosis of rhodopsin-positive debris by both human 
RPE cell types (Figure  3a). To confirm that human RPE cells were 
functional in the host retina, we monitored autofluorescence (AF) 
as a biomarker of phagocytosis and visual cycling. We observed a 
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clear difference in the distribution pattern of AF between grafted, 
nongrafted regions, and sham-injected eyes. Grafted areas of 
 RPE-injected eyes (either from hESC- or hiPSC-derived cells) pre-
sented lower levels of AF, showing a punctate pattern localized near 
the RPE layer, whereas nongrafted areas of the same RPE-injected 
eyes or sham-injected eyes showed high AF levels, with a thick and 
diffuse pattern filling the whole subretinal space (Figure 3b).
We next analyzed the ultrastructure of the grafted areas in 
 RPE-injected eyes at 12 weeks PI. Sham-injected eyes presented a 
loss of photoreceptor nuclei and a thickening of the debris layer, 
consisting of membranous waste material originating from the 
unphagocytosed rod OS (Figure 4a). We observed alterations in the 
ultrastructure of the retina of RCS sham-injected eyes in comparison 
with Long–Evans wild-type eyes. Specifically, the number of basal 
infoldings was diminished and many vacuolar-like spaces contain-
ing membrane-bound degenerated organelles were observed 
(Figure 4b and Supplementary Figure S3). No ultrastructural altera-
tions of Bruch’s membrane were observed in any of the eyes studied 
(Figure 4c). In grafted areas of RPE-injected eyes, the number of RPE 
basal infoldings and morphology were recovered in the area close 
to the transplanted cells (Figure  4b–d), and many round phago-
somes packed with OS disk membranes were evident in these 
regions (Figure  4d), but not in sham-injected eyes. At the same 
time, an amelioration of organization in several OS was observed in 
 RPE-injected eyes (see Supplementary Figure S3).
Protection of rat photoreceptors against gliosis and apoptosis by 
RPE cell replacement
By immunostaining retinas at 5 weeks PI, we studied expres-
sion levels and distribution of GFAP, an indicator of retinal stress, 
and found decreased levels in the grafted areas compared with 
nongrafted areas of the same eyes and with sham-injected eyes 
(Figure  5a). Moreover, in grafted areas the expression of this pro-
tein was restricted to the optic nerve fiber, the ganglion cells, and 
the inner plexiform layers, whereas in nongrafted areas and sham-
injected eyes GFAP was also detected in the inner and outer nuclear 
layers (INL and ONL), showing a more severe gliosis phenomenon 
Figure 1 Characterization of differentiated RPE cells. (a) Electron micrograph showing basal nuclei and apical microvilli (left panel), melanin granules 
(central panel) and tight junction establishment (right panel) at 12 weeks of differentiation. (b) Immunocytochemical analysis of differentiated cells 
confirming protein expression of genes responsible for neural retina and RPE development (PAX6, MITF, CHX10 and OTX2) and markers of mature RPE 
(BEST1, RPE65 and ZO-1). Pluripotency marker OCT4 started decreasing after 4 days of differentiation. Positive PAX6 and MITF cells were negative for 
OCT4 marker (data not shown). (c) Gene expression profile by real-time PCR of differentiated RPE cells. Undifferentiated hPSC cell sample was used as 
the zero set point (control). Images shown in a and b sections were obtained in hiPSC differentiated cells, but comparable results were observed in 
hESC-derived cells. a Bars = 2 µm (left panel); 1 µm (middle panel); 0.2 µm (right panel). b Bar = 50 µm. Data are presented as mean ± SEM. RPE, retinal 
pigment epithelium.
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P21 5 11 12 14
8 12 15 4
12 12 12 4
P42 5 4 4 4
Total (n) 39 43 26
The number of eyes (n), the type of injected material (hESC- or hiPSC-RPE, 
or medium), the postnatal day of injection (P21 or P42), and the week of 
euthanasia (5, 8 or 12 weeks PI) are shown for each group.
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in regions and eyes that did not receive the cell treatment. Likewise, 
we explored the capacity of human transplants to delay the activa-
tion of photoreceptor-programmed cell death in RCS rats. By per-
forming TUNEL (terminal deoxynucleotidyl transferase-dUTP nick 
end labelling) analyses on retina cryosections, we noted a strong 
and consistent reduction in the number of apoptotic photorecep-
tor cells when comparing grafted versus nongrafted areas and 
 sham-injected eyes (Figure  5b). Similar results were obtained in 
hESC- and hiPSC-grafted areas, as both gliosis and apoptosis param-
eters were reduced in all cases.
Therapeutic effect of human transplanted cells during retinal 
degeneration
At 5 weeks PI of P21 injected rats, retinal layers were better con-
served in grafted areas. This preservation extended beyond the 
transplanted region covered by the graft (Figure 6a,b). In particu-
lar, grafted areas displayed inner and outer segments (IS + OS) that 
were longer than the comparable measurements in nongrafted 
areas or in sham-injected eyes in all conditions. Despite the progres-
sion of the disease, grafted areas of RPE-injected eyes showed the 
same degree of preservation (around 30–40%) at 5, 8, and 12 weeks 
after injection (Figure 6c).
Consistent with these observations, we also found that the num-
ber of ONL cell rows was preserved up to 12 weeks PI, showing 70% 
of preservation in the injected regions at all stages. In particular, at 
5 weeks PI ~10 cell rows were preserved in grafted areas, compared 
with only 3 rows detected in nongrafted areas or in  sham-injected 
eyes. The protection against degeneration was maintained until 8 
weeks PI, since the number of ONL cell rows was almost the same 
as at 5 weeks PI. Nevertheless, the decrease in the number of rows 
with age was evident at 12 weeks PI, when it diminished from 10 
to 5–6. Despite this, the number of nuclei rows was still higher in 
grafted areas than in nongrafted areas or sham-injected eyes, where 
a discontinuous single layer of nuclei could be observed (Figure 6c). 
No significant differences were observed when comparing IS + OS 
thickness or ONL cell rows between hESC- or hiPSC-injected eyes.
Interestingly, in grafted areas of P21 RPE-injected rats, we could 
accurately delineate the three nuclear layers (ONL, INL, and GCL) 
and the two plexiform layers (IPL and OPL) for up to 12 weeks, in 
contrast with the overlapping INL and ONL observed in nongrafted 
areas and in sham-injected eyes from 8 weeks PI (see Supplementary 
Figure S4a,b).
In an attempt to outline the benefits of these cell therapies when 
applied to an advanced degenerated eye, we also transplanted 
animals at 42 days of age (P42) and their eyes were histologically 
analyzed at 5 weeks PI. Here, no differences were observed in terms 
of IS  +  OS thickness between groups, while the number of ONL 
cell rows did show a certain level of preservation in grafted areas 
of both hESC- and hiPSC-injected eyes (more than four cell rows 
were maintained in comparison with the single cell row observed 
in nongrafted areas of the same eyes or in sham-injected eyes) (see 
Supplementary Figure S5c,d).
No tumor formation was observed in the histological examina-
tions during the entire study.
Preservation of electroretinographic activity in RCS rats after stem 
cell-based RPE therapy
The preservation of visual function was statistically significant 
in grafted areas of P21 injected rats when stimulated at 4,000 or 
16,000 cd·seconds/m2 at 5 weeks PI (Figure 7a,b). Indeed, the mean 
b-wave amplitude of both hiPSC-RPE- and hESC-RPE-injected 
regions was similar, but significantly higher than the amplitudes 
observed in nongrafted areas or in sham-injected eyes (around 40% 
higher at 4,000 cd·seconds/m2, and 46% at 16,000 cd seconds/m2). 
Although at 8 weeks PI b-wave amplitudes were clearly attenuated, 
preservation of retinal function was still observed since focal elec-
troretinography (ERG) recordings also showed significant rescue in 
grafted areas. However, by 12 weeks PI, b-wave amplitudes became 
nonexistent and no differences were observed between the groups.
In the animals injected at P42, no visual response was detected 
at 5 weeks PI, neither in grafted areas nor in nongrafted areas or 
 sham-injected eyes (data not shown).
DISCUSSION
We successfully established an efficient and reproducible method 
of RPE cell production from hESCs and hiPSCs. We were able to iso-
late and purify RPE cells from both cell lines by selecting pigmented 
colonies of cobblestone-shaped cells. Both RPE cell lines were char-
acterized and the expression of RPE-specific markers confirmed the 
cell lineage.
Once differentiated, human cells were transplanted by 
 trans-scleral injection into the subretinal space of the rat retina (see 
Figure 2 Human cells survive and integrate within the host tissues. (a) 
Fundus images showing the location of the grafted cells within the 
subretinal space of RCS rat after transplantation at day 0 (middle panel) 
and after 6 days (right panel). Green fluorescence observed is emitted 
from Cell Tracker, which was used to label transplanted cells transiently. 
(b) Immunohistochemical analysis was performed to visualize the human 
cells distribution among rat retina layers at 5 weeks PI of P21 injected 
rats. Human cells are shown in green, stained with a cocktail of  human-
specific markers (HSM). Human cells were found in three different 
locations: (i) adjacent to the host RPE, (ii) in the subretinal space adopting 
laminar or (iii) rosette-like structures. These images were obtained in 
hiPSC-injected eyes and are shown as representative examples, but 
similar results were achieved in hESC-injected eyes. (c) A RPE flat mount 
preparation of a hESC-injected eye after 12 weeks of transplantation 
shows the establishment of tight juntions (ZO-1) between the human 
cells themselves and the human and rat cells. Asterisks (*) denote rat 
cells, which are larger and are not stained by human nuclei marker. 
RCS, Royal College of Surgeons; RPE, retinal pigment epithelium; SRS, 
subretinal space; ONL, outer nuclear layer; ONL, outer nuclear layer; INL, 
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Supplementary Video S1). At 5 weeks PI, we found human cells in 
proximity to the host RPE, forming multilayered aggregates in the 
subretinal space, or integrated as a monolayer. Irrespective of the 
graft location, ONL was preserved in all cases, indicating that proper 
integration of human cells in the host RPE would not be a major 
problem for the treatment to become efficient. Nevertheless, it 
would be interesting to determine which factors are responsible for 
graft localization, and whether or not heterogeneous graft location 
could be controlled to reach a more reliable, accurate, and repro-
ducible method of cell transplantation and integration. Despite the 
heterogeneity, human cells were always found close to the RPE and, 
contrary to other studies,28 they were never found invading cellular 
layers of the neural retina. This is of high clinical relevance, since the 
integration of the injected cells into cell layers other than the RPE 
would alter the structure of such a complex tissue where the proper 
connections among different cell types are essential to transmit the 
electrical signal accurately.
Our findings support the view that grafted cells are able to estab-
lish tight junctions between each other and with host RPE cells, as 
shown by ZO-1 staining. These cell–cell adhesions are crucial not 
only for the maintenance of the blood–retinal barrier, but also for 
preserving the morphological integrity of the tissue, and for con-
trolling the differentiation and proliferation of epithelial cells.31 In 
fact, we have shown that grafted cells are positive for CRALBP (a 
typical RPE marker) and do not express Ki67 (an indicator of prolif-
eration). Thus, the appropriate formation of these junctions among 
grafted cells might be imperative to sustain their RPE cell fate and 
inhibit their proliferation, two key aspects in terms of functionality 
and safety of the procedure.
One critical role of RPE includes the maintenance of photore-
ceptor integrity by daily phagocytosis of photoreceptor debris,1 a 
function that is impaired in RCS rats owing to the recessive Mertk 
mutation. Here, we showed that grafted cells were able to replace 
the function that the host RPE lacks and restore phagocytosis of 
the OS in the RCS rat retina, since rhodopsin granules were found 
within the human cells and phagosomes were present in RPE cells 
at the grafted area after 12 weeks of injection. The restoration of 
RPE phagocytosis had beneficial effects on retinal morphology as 
we found that photoreceptor OS were better preserved in grafted 
areas. Moreover, AF levels were clearly decreased in grafted areas, 
compared with the thick and diffuse AF signal present in nongrafted 
areas and sham-injected eyes. Notably, we have shown that AF in 
grafted areas was almost abolished, in contrast with other stud-
ies where AF of transplanted regions was not completely reduced, 
where transplanted cells could be undergoing premature ageing or 
performing an incomplete ingestion process.30 If true, the slight AF 
observed in our study might be due to a better preservation of the 
photoreceptor/RPE complex.32
The presence of human cells in the RCS rat subretinal space was 
capable of slowing down the progression of the disease. At histologi-
cal levels, the rate at which the photoreceptor nuclei were lost was 
lower in grafted than in nongrafted areas and sham-injected eyes. 
We also found that at 5 and 8 weeks PI programmed cell death was 
activated in areas that did not receive the cell therapy. Similarly, GFAP 
Figure 3 Transplanted cells maintain RPE cell marker expression, phagocytosed rhodopsin material, and decreased autofluorescence levels at 5 weeks 
PI. (a) Grafted cells are positive for CRALBP and mostly negative for Ki67. Rhodopsin-positive material is found within the cell membrane of HSM-
labelled cells. (b) Autofluorescence in sham-injected eyes and in nongrafted areas was detected scattered all over the SRS, whereas in grafted areas it 
was limited to discrete spots of the RPE cell layer. Representative images of hiPSC-injected eyes are shown, but similar results were obtained in hESC-
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was upregulated in nongrafted areas and in  sham-injected eyes. This 
implies an activation of reactive gliosis in astrocytes and Müller cells, 
which usually leads to their hypertrophy onto the photoreceptor 
and vitreal surfaces. Besides, and contrary to grafted areas, prolonga-
tions of GFAP-expressing cells reached the outer retina, where GFAP 
upmodulation has been previously associated with a disruption of 
the RPE and the blood–retina barrier.33 Taken together, these results 
showed how the transplanted cells successfully protected the retina 
from both apoptosis and glial stress. Nevertheless, despite this clear 
effect slowing down disease progression, human RPE cells were only 
able to delay photoreceptor apoptosis for up to 8 weeks. However, at 
12 weeks PI, we could still demonstrate a certain degree of ONL pres-
ervation in proximity to the grafts. A relationship between the thick-
ness of the ONL and the electroretinographic activity could be estab-
lished, since at 5 and 8 weeks PI grafted areas with preserved ONL cell 
row number displayed improved ERG responses compared with non-
grafted regions. Nevertheless, as similarly observed in other studies,12 
at 12 weeks PI, the retina did not respond to light stimuli anymore, 
which suggests that a minimum number of ONL cell rows are nec-
essary to trigger the visual signal cascade. In this sense, it would be 
interesting to investigate novel methods to better sustain the preser-
vation of photoreceptor cells and maintain photoreceptor survival for 
longer time periods. For this, several aspects should be considered: 
first, the number of transplanted cells could be one of the limiting 
factors; low numbers of cells might not be sufficient to reduce the 
progression of the disease, but transplantation of a high number of 
cells in the limited subretinal space could disorganize the multilay-
ered structure of the retina. Second, the use of protocols based on 
repeated cell injection could be considered, but would not ensure 
long-term photoreceptor maintenance since our results support that 
Figure 4 Light and electron microscopy images from WT rats, sham- and RPE-injected RCS rats. (a) Semi-thin section stained with methylene blue 
showing a thickness reduction in the outer nuclear layer and a thick debris layer of unphagocytosed rod outer segments in a RCS sham-injected rat. 
(b, c) A reduction of RPE basal infoldings and the presence of vacuole-like spaces (asterisk) can be seen at ultrastructural level in sham-injected RCS 
rats. This lesion was restored in RPE-injected RCS rats. (d) Autophagosomes (arrow) containing outer segment disk membranes were observed in RPE-
injected RCS rats. Bars: a, 27 µm; c, 1.2 µm; d, 0.97 µm. BI, basal infoldings; BM, Bruch’s membrane; ChV, choroidal vessel; Me, melanosome; GCL, ganglion 
cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; DL, debris layer; RPE, retinal pigment epithelium; OS, outer segment.
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at 12 weeks PI human cells were still grafted. In fact, recent work has 
shown that a second transplantation cannot prolong the therapeu-
tic effect.34 Third, RPE could be combined with photoreceptor trans-
plantation, to replace damaged cells as well as to provide support to 
both transplanted and still healthy host photoreceptors. However, it 
is worth noting that the RCS rat model displays a more severe phe-
notype and faster retinal degeneration than humans affected by RP 
disease, which typically lose night vision in adolescence, side vision in 
young adulthood, and central vision later in life.3 Therefore, the “RPE-
alone” cell therapy may prevent photoreceptor cells from degenera-
tion during longer periods in humans than in rats.
To determine the feasibility of cell replacement therapy as a 
generic treatment for retinal disease, transplantation must be 
assessed at different stages of retinal degeneration to define the 
potential breadth of application and to outline therapeutic time 
windows.35 For this reason, we tested the effect of RPE cell therapy 
at two different disease stages: P21 and P42. Previous work had 
found that grafts were totally ineffective at the latter time point,20 
but here, as also found by Wang et al.36 grafting ARPE-19 cells, we 
showed that the human RPE-derived cells transplanted at P42 were 
able to preserve the retina from degeneration in terms of ONL cell 
rows. However, ERGs responses were null in grafted, nongrafted 
areas, and in sham-injected eyes when transplanted at P42, high-
lighting the need to perform transplantation at early stages of the 
disease to effectively rescue the photoreceptors cells.
The increased visual response and preservation of ONL observed 
in grafted areas could be due to a direct effect of human RPE cells 
on photoreceptor debris phagocytosis and visual cycle, or to a 
paracrine neuroprotective effect. Our in vitro expression assays of 
differentiated RPE cells showed increased expression of PEDF, a 
neurotrophic growth factor known to exert protective effects on 
retinal neurons.37,38 These data, together with the fact that the area 
of preservation extended beyond the defined region covered by 
the graft, suggest that PEDF or other “diffusible neuroprotective fac-
tors” might be partially responsible for the rescue of the phenotype. 
In this regard, several studies based on intravitreous injections of 
PSC-derived RPE cells or subretinal transplantation of fibroblasts or 
feeder cells have shown that at least some cell-specific features are 
required for the beneficial effects of the treatment.12,34,39
Over the last decades, gene therapy has shown a great potential 
to treat diseases with a genetic component, inherited RD among 
them. However, the use of this technique requires identifica-
tion of the molecular cause in each patient and this is particularly 
complicated in RP cases owing to the genetic complexity of the 
disease. Moreover, gene therapy is not suitable for approximately 
the 40% of RP cases that currently remain genetically unsolved.40 
Taken together, these obstacles highlight the need of a “universal” 
therapeutic approach that uniformly treats all different forms of RP. 
Within this context, stem cell-based treatments might be an excel-
lent therapeutic strategy, since it is appropriate not only for the 
genetically diagnosed RP cases, but also for those patients affected 
by orphaned or novel genes, or by genetically complex RD, such as 
age-related macular degeneration and diabetic retinopathy.
To the best of our knowledge, this is the first report comparing the 
therapeutic effects of human RPE cells differentiated from human 
embryonic stem cells and human-induced pluripotent stem cells. Our 
data clearly show that RPE derived from either PSC source are equally 
effective in protecting the retina of RCS rats from degeneration. 
However, several aspects other than effectiveness must be taken into 
account when choosing the appropriate cell-based therapy for RPE 
Figure 5 Human cells reduce gliosis and apoptosis of rat retinas. (a) Reactive gliosis detected by immunofluorescence with the GFAP antibody was 
clearly decreased in grafted regions compared with nongrafted regions of the same eye and with sham-injected eyes. (b) TUNEL analysis showed a 
clear reduction in the number of photoreceptor apoptotic nuclei in grafted regions of RPE-injected eyes. Note that all pictures were obtained using the 
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regeneration in humans, including safety issues and considerations 
of reproducibility, scalability, and affordability, and as well as being 
ethically acceptable.41 At any rate, building on the positive results 
obtained here from the transplantation of the two cell lines, more 
experiments are warranted with a higher number of samples, to be 
able to confirm that iPSCs derived from different cell lines and differ-
ent cell types are suitable for differentiation into RPE, and whether all 
of them behave as observed in this work.
MATeRIAl AND MeTHODS
Cell culture and differentiation
Two human pluripotent stem cell lines (hPSC), one hiPSC 
(CBiPSC30-4F-5) and one hESC (ES[4]), were differentiated into RPE 
cells following the Idelson et al. protocol12, with minor modifications 
(see Supplementary Materials and Methods and Supplementary 
Figure S1).
Immunocytochemistry of differentiated cells
Once differentiated, the hPSC-derived RPE cells were charac-
terized by immunocytochemistry to determine the extent of 
expression of the retinal and RPE differentiation markers. Cells 
were grown in polystyrene slide-flasks and fixed with 4% (w/v) 
paraformaldehyde for 20 minutes at room temperature (RT). 
The immunodetection was performed with TBS/0.2% (v/v) Triton 
X-100 for permeabilization, and samples were blocked using a 
solution containing 3% (v/v) goat serum, 1% (v/v) BSA, and 0.3% 
(v/v) Triton X-100 in PBS for 1 hour at RT. Primary antibodies were 
incubated at 4 °C overnight, and secondary antibodies were 
Figure 6 Photoreceptor cell layers are preserved in grafted areas. (a) Images of H&E-stained sections showing preservation of layers in proximity to 
a subretinal RPE graft (located between arrows) compared with thin layers distant from the graft. (b) Higher magnifications clearly showed retinal 
cell layer preservation in proximity to grafted cells (asterisk). (c) IS+OS thickness as well as the number of ONL cell rows were significantly increased 
in grafted areas compared with nongrafted areas and sham-injected eyes up to 12 weeks PI. There was no statistically significant difference between 
eyes injected with hiPSC (n = 8) or hESC (n = 5) for IS+OS thickness or number of ONL cell rows. Bar: b, 100 µm. Data are presented as mean ± SEM, 
***P < 0.0001. RPE, retinal pigment epithelium; SRS, subretinal space; ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion cell layer, IS, inner 
segment, OS, outer segment.
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incubated at 37 °C for 2 hours. The antibodies used are listed in 
the Supplementary Table S1. Undifferentiated hPSC were used as 
negative controls. Samples were mounted in Fluoroshield with 
DAPI, and images were obtained on an SPE confocal microscopy 
(Leica Microsystems, Wetzlar, Germany).
Determination of RNA expression by quantitative real-time PCR
Samples from hPSC-derived RPE were taken from each cell line 
differentiation culture. Cells were treated with Trizol reagent and 
RNA was isolated using RNeasy RNA isolation kit (Qiagen, Hilden, 
Germany) following the manufacturer’s instructions. RNA was 
quantified using NanoDrop, and cDNA was synthesized from 1 μg 
total RNA per sample using the Cloned AMV First-Strand Synthesis 
Kit (Invitrogen, Life Technologies, Carlsbad, CA). Quantitative real-
time PCR (qRT-PCR) was performed with Platinum SYBR Green quan-
titative PCR super mix (Invitrogen, Life Technologies) with 25 ng 
cDNA per well. Relative gene expression was assayed in triplicate, 
and compared with the undifferentiated hPSC cell sample, which 
served as the zero set point. All qRT-PCR reactions were performed 
in an Applied Biosystem 7900 HT Fast qRT-PCR System Thermocycler 
following the manufacturer’s instructions. The markers used for 
the analysis of gene expression were CRALBP, DKK-1, MERKT, MITF, 
Figure 7 Visual function is conserved in grafted areas. (a) Fundus image of an RPE-injected RCS rat and its ERG responses are shown as a representative 
example. Focal ERG was used to test the functional rescue of transplanted RPE cells at 5, 8, and 12 weeks PI. For each transplanted eye, three different 
light intensities (500, 4,000 and 16,000 cd seconds/m2) were used to measure the electrical activity, which was recorded over two different spots in each 
eye: one over the grafted area (green circle, i) and other over a region far away from the graft, nongrafted area (red circle, ii). (b) Grafted areas showed 
significantly higher b-wave amplitudes than nongrafted and sham-injected eyes when stimulated with 4,000 or 16,000 cd·seconds/m2. Higher b-wave 
amplitudes were obtained in grafted regions after 5 (n = 9) and 8 (n = 7) weeks PI, while no difference was detected after 12 weeks. At 8 weeks, PI b-wave 
amplitudes were clearly attenuated, but preservation of visual function was still observed. No difference could be detected between hESC- or hiPSC-
injected eyes. Data are presented as mean ± SEM, *P < 0.01.
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OCT3/4, OTX2, PAX6, PEDF, RHH, RX, SIL, and TYR. GAPDH was used 
for normalization. Primer sequences are given in Supplementary 
Table S2.
Transplantation of differentiated cells into the RCS rat
Before surgery, cells were harvested and transiently labelled with 
20 µmol/l Cell Tracker Green CMFDA (Life Technologies, Cat. No. 
C2925) for 30 minutes at 37 °C, and then washed and suspended 
in the RPE differentiation medium at a density of 5 × 104 cells/µl. 
Roughly 100,000 cells in suspension were transplanted into the 
subretinal space of RCS rats as previously described by Warfvinge 
et al.,42 but with minor modifications (see Supplementary Materials 
and Methods and Supplementary Video S1).
We initially injected 123 eyes, 95 of them with RPE-differentiated 
cells, and 28 with differentiation medium (Table  1). Following 
transplantation, the fundi of the rats were visualized in a Micron 
III platform (Phoenix Research Laboratories, Pleasanton, CA), and 
green fluorescence was used to determine both the injection site 
and the subretinal area covered by the transplanted cells at the 
time of injection. We excluded those eyes that did not present an 
observable fluorescent bleb of cells in the subretinal space, the 
cases in which injected cells were found in the vitreous and, eyes 
where major hemorrhage was caused by the intervention (n = 15). 
Thus, we included in the final study 108 eyes: 82 RPE-injected 
eyes (39 injected with hESC-derived RPE cells and 43 with hiPSC-
derived RPE) and 26 sham-injected eyes. To assess the efficacy of 
the treatment in distinct phases of retinal degeneration, animals 
were injected either at P21, when the first morphological changes 
can be noticed in the retina, or at a later stage of the disease, P42, 
when apoptosis has already caused the death of a significant 
number of photoreceptor cells.43,44 RPE- and sham-injected eyes 
were monitored at 5, 8 or 12 weeks PI. Accordingly, animals were 
divided into groups on the basis of the type of injected material 
(hESC-, hiPSC-derived RPE cells, or medium), the postnatal day of 
injection (P21 or P42), and the end of the experiment (5, 8 or 12 
weeks PI) (Table 1).
Immunosuppression by cyclosporin A
To prevent transplant rejection, animals were immune sup-
pressed by the addition of 21 mg/kg/day of cyclosporin A (CsA) 
(Novartis, Cat. No. 653833.3) to 1 ml of sucralose (Clear H2O, Cat. No. 
 74-02-5022), starting the treatment 2 days before the injection and 
maintaining it throughout the whole experiment. Every 2–3 weeks 
from the beginning of the treatment, a complete blood count (CBC) 
(BC-2800Vet, Minidray) on 20 μl of peripheral blood provided the 
state of immune suppression of the animals. Independently from 
the period of treatment, all animals were successfully immune sup-
pressed, showing white blood cell levels below the reference range, 
with no major alterations in the other hematological parameters 
(see Supplementary Figure S5).
Histology
Fourteen-micrometer cryosections on polylysine-covered slides 
were fixed with a mixture of methanol and acetic acid (95:5 v:v) for 
1 minute at −20°C and stained with hematoxylin/eosin by standard 
protocols to assess the injection site, retinal lamination and any evi-
dence of tumor formation. ImageJ software was used to measure 
the number of cell rows of the ONL and the thickness of the inner 
(IS) and OS of RPE- and sham-injected eyes. For the RPE-injected 
eyes, two measurements were taken in the same eye: one over the 
grafted area and another over the nongrafted area, distant from the 
injection site. For statistical analyses, the significance was calculated 
with ANOVA, followed by the Tukey test.
Immunohistochemistry
Eyes were excised, frozen in OCT (Tissue-Tek, Sakura Finetech, 
Torrance, CA) and sectioned for histological and immunohisto-
chemical analyses, or the RPE was removed intact as a flat-mount 
preparation.
Immunostaining of cryosections. Slides were dried for 1 hour at 
RT, fixed with paraformaldehyde 4% (w/v) (Electron Microscopy 
Sciences Cat. No. 15710, Hatfield, PA) for 20 minutes at 37 °C, and 
washed with PBS. Samples were blocked for 1 hour at RT with a 
solution containing 3% (v/v) sheep serum, 1% (v/v) BSA and 0.3% 
(v/v) Triton X-100 in PBS and incubated over night at 4 °C with 
the primary antibody of interest. Sections were rinsed with PBS 
and incubated for 1 hour at RT with the corresponding secondary 
antibody. Sections were mounted in Fluoroshield with DAPI  (Sigma-
Aldrich, Cat. No. F6057, St. Louis, MO) and analyzed by confocal 
microscopy (FV1000 Olympus, Center Valley, PA). Details of the 
antibodies and dilutions used for immunofluorescence, including 
the human-specific marker antibody cocktail (HSM), are listed in 
Supplementary Table S1.
Immunostaining of flat-mount preparations. Eyes were enucleated 
with the aid of a dissecting microscope. The anterior segment and 
lens were removed, and the retinas were detached, separated from 
the optic nerve head with fine-curved scissors, and discarded. 
Radial cuts were made towards the optic nerve head, and the 
sclera–choroid–RPE complexes (eyecups) were fixed in 100% 
methanol for 30 minutes at −20 °C. After fixation, eyecups were 
washed with PBS containing 0.1% (v/v) Triton X-100, blocked with 
PBS containing 0.1% (v/v) Triton X-100 and 1% (v/v) BSA for 1 hour 
at RT and incubated overnight at 4 °C with the primary antibodies 
of interest. Thereafter they were washed and incubated with the 
corresponding secondary antibodies for 1 hour. Posterior segments 
were washed in PBS, flat mounted in Fluoroshield with DAPI and 
analyzed by confocal microscopy (FV1000 Olympus). Antibodies 
and dilutions used for immunofluorescence in flat-mounted eyes 
are listed in Supplementary Table S1.
Transmission electron microscopy
hPSC-derived RPE homogeneous culture samples were fixed with 
2.5% (w/v) glutaraldehyde for 2 hours at 4 °C. Postfixation was car-
ried out in 1% (w/v) osmium tetroxide for 2 hours at 4 °C, and sam-
ples were then dehydrated with ethanol and embedded in epoxy 
resin. Semithin and ultrathin sections were analyzed. Samples were 
examined in a Jeol 1011 transmission electron microscope (Jeol, 
Tokyo, Japan).
Ocular samples containing retina, RPE, choroid, and sclera were 
dissected out of from RPE- and sham-injected eyes. In addition, com-
parable samples from noninjected Long–Evans wild-type rats were 
obtained. Samples were fixed in 2.5% (v/v) glutaraldehyde and 2% 
(w/v) paraformaldehyde and postfixed in 1% (w/v) osmium tetroxide. 
After staining in aqueous uranyl acetate, samples were dehydrated 
and embedded in epoxy resin. Semithin sections stained with methy-
lene blue were examined by light microscopy and ultrathin sections 
(70 nm) stained with uranyl acetate and lead citrate were examined in 
a Jeol 1400 transmission electron microscope (Jeol).
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TUNEL analyses
Fourteen-micrometer cryosections on polylysine-covered slides 
were fixed with paraformaldehyde 4% (v/v) for 20 minutes at 37 °C, 
washed with PBS, and permeabilized with proteinase K (20 µg/ml) 
for 15 minutes at RT. The TUNEL reaction was performed using the 
Click-iT Plus TUNEL Assay (Life technologies, Cat. No. C10617) fol-
lowing the manufacturer’s instructions. A positive control section 
was obtained by inducing DNA strand breaks with 1 unit of DNAse I. 
A negative control section was treated with a TUNEL cocktail lacking 
the TdT enzyme. Sections were mounted in Fluoroshield with DAPI 
(Sigma-Aldrich, Cat. No. F6057) and analyzed by confocal micros-
copy (FV1000 Olympus).
Focal ERG
To assess transplantation efficiency, retinas were examined at 5, 8, 
and 12 weeks PI by live imaging and focal ERG, which allows the 
measurement of the visual response limited to particular areas. 
Recordings were measured using the Micron III platform (Phoenix 
Research Laboratories). Dark-adapted rats (12–16 hours) were anaes-
thetized under dim red light with 2% (v/v) isoflurane gas and placed 
on a heating pad at 37 °C. Pupils were dilated with a topical mixture 
of phenylephrine and tropicamide, and recordings were measured 
as previously described.30 A spot of ~2 mm diameter on the retina 
was stimulated at different light intensities (500, 4,000, and 16,000 
cd·seconds/m2) over two distinct regions of RPE-injected eyes, the 
grafted area and the nongrafted area, and over the injected area of 
sham-injected eyes. At least five ERG traces were obtained for each 
condition and results averaged. The amplitude and the implicit time 
of the b-wave were calculated using the Labscribe2 software. For 
statistical analyses, the significance was calculated with ANOVA fol-
lowed by Tukey test.
All procedures on RCS rats were carried out with the approval of 
the Ethics Committee for Animal Experimentation of the Hospital 
Universitari Vall d’Hebron, and in accordance with the ARVO 
Statement for the Use of Animals in Ophthalmic and Vision Research 
and with the Declaration of Helsinki.
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